Can B cells break the bound­aries of cell ther­a­py? Long­wood start­up has $52M to prove a new en­gi­neer­ing tech

Back in De­cem­ber 2017, as the cell ther­a­py world was still bask­ing in the vir­tu­al­ly back-to-back ap­provals of two pi­o­neer­ing CAR-Ts, re­searchers at Seat­tle Chil­dren’s Re­search In­sti­tute re­port­ed a sci­en­tif­ic first in a dif­fer­ent cor­ner of the field: en­gi­neer B cells to treat dis­ease.

Aleks Radovic-Moreno

The team, led by David Rawl­ings and Richard James, even­tu­al­ly worked with Long­wood Fund to start a biotech around those find­ings. And now At­las Ven­ture and RA Cap­i­tal Man­age­ment are com­ing on board to lead a $52 mil­lion launch round, joined by Al­ta Part­ners, for Be Bio­phar­ma.

“B cells have been such an at­trac­tive cell type,” Aleks Radovic-Moreno, an en­tre­pre­neur-in-res­i­dence who co-found­ed the biotech, told End­points News. “It just wasn’t their time yet. But now we feel con­fi­dent that it’s their time to step in­to the lime­light.”

The two clas­sic stum­bling blocks, he added, are fig­ur­ing out how to en­gi­neer them ef­fi­cient­ly and cul­ture them in suf­fi­cient quan­ti­ties.

David Rawl­ings

But once Rawl­ings and James cracked the code through ho­mol­o­gy-di­rect­ed re­pair, it opened up po­ten­tial ap­pli­ca­tions be­yond what cur­rent cell ther­a­pies can do. While T cells are de­signed to kill cells marked by cer­tain anti­gens, B cells’ unique func­tion is that they make “un­be­liev­able quan­ti­ties of pro­teins” — from an­ti­bod­ies to im­mune mod­u­lat­ing fac­tors.

You can al­so pro­gram a B cell to go to a spe­cif­ic tis­sue, with­out the need for con­di­tion­ing or lym­phode­ple­tion, while re­tain­ing an op­tion to titrate and re­dose if you don’t get it right the first time.

“If you think about what dis­ease you want where you want a pro­tein to be se­cret­ed in a tar­get­ed fash­ion, that’s ac­tu­al­ly a re­al­ly big list,” Radovic-Moreno said, list­ing can­cer, au­toim­mune dis­eases, mono­genic dis­or­ders and in­fec­tious dis­eases as ar­eas be­ing ex­plored.

Richard James

In a pre­vi­ous in­ter­view, James al­so gave he­mo­phil­ia B as an ex­am­ple of a pro­tein de­fi­cien­cy dis­ease where a B cell ther­a­py can po­ten­tial­ly cure pa­tients.

Be Bio ben­e­fits from the trail that hun­dreds of T cell ther­a­py play­ers have now trav­eled, step­ping in­to a world where lo­gis­tics, ge­net­ic mod­i­fi­ca­tion and cell pu­rifi­ca­tion tools are read­i­ly avail­able. But its core area of ex­per­tise — map­ping out the bi­ol­o­gy of B cells and ma­nip­u­lat­ing them — re­mains one that’s on­ly hous­ing aca­d­e­m­ic groups so far.

David Stein­berg

Cur­rent­ly man­aged by an in­ter­im team con­sist­ing of Radovic-Moreno as pres­i­dent and David Stein­berg as CEO, the team is grow­ing every week at the Alexan­dria Launch­Labs in Kendall Square. In ad­di­tion to the sci­en­tif­ic founders, it’s al­so guid­ed by an il­lus­tri­ous sci­en­tif­ic ad­vi­so­ry board, con­sist­ing of Frances Eun-Hyung Lee, an asth­ma ex­pert at Emory, as well as Har­vard’s Shiv Pil­lai and UCSF’s Ja­son Cys­ter, who bring years of ex­pe­ri­ence study­ing B cells.

He may not be ready to dis­cuss con­crete drug tar­gets or time­lines yet, but for Radovic-Moreno, who played a lead­ing role in get­ting Sid­dhartha Mukher­jee’s en­gi­neered hematopoi­et­ic stem cells off the ground at Vor Bio, it’s all rem­i­nis­cent of the ear­ly days of T cell work.

“I wouldn’t be sur­prised if we see a sim­i­lar tra­jec­to­ry 5 years from to­day,” he said. “I don’t think there will be hun­dreds of B cell com­pa­nies, but I’m gonna bet it’s more than one.”

A new era of treat­ment: How bio­mark­ers are chang­ing the way we think about can­cer

AJ Patel was recovering from a complicated brain surgery when his oncologist burst into the hospital room yelling, “I’ve got some really great news for you!”

For two years, Patel had been going from doctor to doctor trying to diagnose his wheezing, only to be dealt the devastating news that he had stage IV lung cancer and only six months to live. And then they found the brain tumors.

“What are you talking about?” Patel asked. He had never seen an oncologist so happy.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

ProFound Therapeutics founding team

Flag­ship's lat­est biotech could turn some of the thou­sands of new pro­teins it dis­cov­ered in­to ther­a­pies — and it has $75M to start

Flagship Pioneering, the incubator of Moderna and dozens of other biotechs, says it has landed upon tens of thousands of previously undiscovered human proteins. The VC shop wants to potentially turn them into therapeutics.

Like other drug developers that have turned proteins into therapeutics (think insulin for diabetes), Flagship’s latest creation, ProFound Therapeutics, wants to tap into this new trove of proteins as part of its mission to treat indications ranging from rare diseases to cancer to immunological diseases.

Richard Silverman, Akava Therapeutics founder and Northwestern professor

This time around, Lyri­ca's in­ven­tor is de­vel­op­ing his North­west­ern dis­cov­er­ies at his own biotech

Richard Silverman was left in the dark for the last five years of clinical development of the drug he discovered. The Northwestern University professor found out about the first approval of Lyrica, in the last few days of 2004, like most other people: in the newspaper.

What became one of Pfizer’s top-selling meds, at $5 billion in 2017 global sales before losing patent protection in 2019, started slipping out of his hands when Northwestern licensed it out to Parke-Davis, one of two biotechs that showed interest in developing the drug in the pre-email days, when the university’s two-person tech transfer team had to ship out letters to garner industry appetite.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Peter Thompson, Terremoto Biosciences interim CEO

For­mer Prin­cip­ia team looks to shake up co­va­lent small mol­e­cules again, this time at 'earthquake' scale

Terremoto Biosciences goes back a long ways, in a sense, to about a dozen years ago when Principia Biopharma was founded by UCSF professor Jack Taunton. Peter Thompson initially helmed the biotech.

The company helped expand covalent small molecule inhibitors beyond oncology and into autoimmune disease by targeting cystine. But that amino acid is uncommon in a lot of proteins, offering fewer drug targets than, say, lysine, which is present in most proteins of interest. So, over the years, Taunton went back to the drawing board to check out that second amino acid.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)

Eli Lil­ly set to in­vest $2.1B in home state man­u­fac­tur­ing boost

Eli Lilly is looking to expand its footprint in its home Hoosier State by making a major investment in manufacturing.

The pharma is investing $2.1 billion in two new manufacturing sites at Indiana’s LEAP Lebanon Innovation and Research District in Boone County, northwest of Lilly’s headquarters in Indianapolis.

The two new facilities will expand Lilly’s manufacturing network for active ingredients and new therapeutic modalities, including genetic medicines, according to a press release.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

Up­dat­ed: US sees spike in Paxlovid us­age as Mer­ck­'s mol­nupi­ravir and As­traZeneca's Evusheld are slow­er off the shelf

New data from HHS show that more than 162,000 courses of Pfizer’s Covid-19 antiviral Paxlovid were administered across the US over the past week, continuing a streak of increased usage of the pill, and signaling not only rising case numbers but more awareness of how to access it.

In comparison to this week, about 670,000 courses of the Pfizer pill have been administered across the first five months since Paxlovid has been on the US market, averaging about 33,000 courses administered per week in that time.

Pfiz­er and CD­MOs ramp up Paxlovid man­u­fac­tur­ing with Kala­ma­zoo plant ex­pan­sion lead­ing the way

As the Covid-19 pandemic continues to evolve, pharma companies and manufacturers are exploring how to step up production on antivirals.

Pfizer is planning to expand its Kalamazoo-area facility to increase manufacturing capabilities for the oral Covid-19 antiviral Paxlovid, according to a report from Michigan-based news site MLive. The expansion of the facility, which serves as Pfizer’s largest manufacturing location, is expected to create hundreds of “high-skilled” STEM jobs, MLive reported. No details about the project’s cost and timeline have been released, but according to MLive, Pfizer will announce the details of the expansion at some point in early June.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.

FDA spells out the rules and re­stric­tions for states seek­ing to im­port drugs from Cana­da

The FDA is offering more of an explanation of the guardrails around its program that may soon allow states to import prescription drugs in some select circumstances from Canada, but only if such imports will result in significant cost reductions for consumers.

While the agency has yet to sign off on any of the 5 state plans in the works so far, and PhRMA’s suit to block the Trump-era rule allowing such imports is stalled, the new Q&A guidance spells out the various restrictions that states will have to abide by, potentially signaling that a state approval is coming.

Simba Gill, CEO of Evelo Biosciences

While down 87% YOY, Evelo gets Flag­ship and oth­ers to in­fuse new cap­i­tal for come­back hope

Just four years after Flagship spinout Evelo Biosciences went public in an IPO worth $85 million, the biotech has seen its share price tank from $13 a share this time last year (ultimately reaching a peak of over $17) to now under $1.50. And today, it looks like Flagship still thinks the fledging biotech, in a down market, is still worth something after initial pre-IPO backing from the likes of Google’s GV, Celgene, Mayo Clinic and Alexandria Venture.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 142,700+ biopharma pros reading Endpoints daily — and it's free.